OptiKira has been awarded a $498,500 grant to support the development of their platform technology for the treatment of ALS (Lou Gehrig's disease). The company's technology prevents progressive cell death and is being developed for a range of degenerative diseases including ALS, retinitis pigmentosa and diabetes. OptiKira is based on the discoveries of Harrington Scholars from UCSF and technology licensed from UCSF and the University of Washington.
OptiKira has been awarded two NIH grants to support the development of novel therapeutics that prevent cell death caused by misfolded or unfolded proteins. The company's technology has application for diseases such as retinitis pigmentosa, diabetes, and ALS.
OptiKira, launched by BioMotiv, is based on technology from Harrington Scholars at University of California, San Francisco, and collaborators from the University of Washington.
BioMotiv, a drug development accelerator associated with The Harrington Project, the University of California, San Francisco (UCSF), and University of Washington, Seattle, are announcing the formation of OptiKira, a platform company that will develop small molecule therapeutics that prevent cell death in pathologies caused by misfolded or unfolded proteins.